Genmab A/S (GMAB) Set to Announce Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) will be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The firm had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Genmab A/S Stock Down 1.6 %

GMAB traded down $0.45 on Tuesday, hitting $28.12. 266,100 shares of the company traded hands, compared to its average volume of 578,592. The company has a 50 day moving average of $29.44 and a 200-day moving average of $29.97. Genmab A/S has a 12-month low of $26.32 and a 12-month high of $42.72. The stock has a market capitalization of $18.59 billion, a PE ratio of 29.76, a PEG ratio of 2.02 and a beta of 0.98.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GMAB. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Truist Financial reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday. BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Finally, Citigroup cut Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.